Recombinant interlukin-2 plus chemotherapy in treatment of multiple myeloma

VernacularTitle:重组人白细胞介素-2联合化疗治疗多发性骨髓瘤
Author: Wei LIU ; Huijuan WANG ; Wen GAO ; Yanchen LI ; Ying HU ; Na AN
Publication Type:Journal Article
Keywords: Interleukin-2; Multiple myeloma; Immunotherapy
From: Journal of Leukemia & Lymphoma 2009;18(11):672-674
CountryChina
Language:Chinese
Abstract: Objective To study the effect of recombinant interlukin-2 plus chemotherapy in treatment of multiple myeloma. Methods We divided into two groups: chemotherapy plus rIL-2 group and simple chemotherapy group. The patients were given at dose of rIL-2 1×l06 IU/d, iH, qd, for 4 weeks and 4cycles. After 4 cycles the changes of T-cell subsets of their peripheral blood were determined. Response was evaluated according to Blad criteria. Adverse events were graded according to the National Cancer Institute Common Toxicity Criteria,version 3.0. Results The positive percentages of CD_3, CD_4 NK, CD_(69) and CD_4/CD_8ratio after chemotherapy in chemotherapy plus rIL-2 group were significantly higher than those before chemotherapy in the same group and those after chemotherapy in the other group. The overall response rate and complete response rate were 66.7 % and 25.0 % vs 50.0 % and 8.3 % respectively. The side effects of rIL-2 were predictable and manageable. Conclusion Recombinant interlukin-2 plus chemotherapy could increase immune function of patients with multiple myeloma and has a higher response rate as compared with simple chemotherapy.